ClinicalTrials.gg
Status unknownNCT05718037Updated Feb 8, 2023

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

A Phase 1 interventional study of Recombinant Zoster Vaccine and Placebo in Herpes Zoster, sponsored by Wuhan BravoVax Co., Ltd.. Status unknown. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Wuhan BravoVax Co., Ltd. · Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
42nd of 46
40 · median 239
Started
2023
with 5 others
Phase 1
5 of 46
none open now
Registered
39th of 46
by date

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 42nd largest by planned enrollment, is one of 6 that started in 2023, is one of 5 in phase 1, and was the 39th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Herpes Zoster Vaccine
  • BV211
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy resident aged 30-70 years with body weight ≥ 50 kg for males and ≥ 45 kg for females, within the range of 19.0-32.0 (including the boundary value), who can provide legal identification.
  • Willing to participate in the study and sign ICF.
  • Women of childbearing age shall take effective measures 30 days before vaccination up to 6 months post full vaccination and not in lactation period. The pregnancy test on the day of vaccination shall be negative.
  • Will attend all scheduled follow-up visits and follow the requirements of the clinical study.

Exclusion criteria

Exclusion Criteria:

  • Smoking, and/or excessive alcohol use.
  • Failed the screening test of illicit drugs, including THC.
  • Axillary temperature above 37.3℃.
  • History of herpes zoster.
  • Received any herpes zoster vaccine.
  • Received any vaccine within 14 days or within 28 days before vaccination.
  • Received gamma immunoglobulin or intravenous immunoglobulin within 3 months before vaccination.
  • Have acute illness or are in the acute exacerbation phase of a chronic disease within 3 days before vaccination.
  • Allergic history to any vaccine-related component; history of severe allergies to any vaccine.
  • History of convulsions, epilepsy or encephalopathy (such as congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection, damage to nerve tissue in brain caused by chemical drug poisoning, etc.) and psychiatric history or family history of mental illness.
  • Asplenia or functional asplenia, and asplenia or splenectomy caused by any reason.
  • Primary or secondary or diagnosed with congenital or acquired immunodeficiency, infection of , lymphoma, leukemia, SLE, JRA, inflammatory bowel disease or other diseases.
  • Received immunosuppressive therapy (such as long-term application of systemic ≥ 14 days, dose ≥ 2 mg/kg/day or prednisone ≥ 20mg/day or equivalent to that dose of prednisone, excluding inhaled, intra-articular and topical steroid) within 3 months before vaccination.
  • Serious cardiovascular diseases (pulmonary heart disease, pulmonary edema), liver and renal diseases and diabetes with complications.
  • History of thrombocytopenia or other coagulation disorders, which may cause to intramuscular injection.
  • Abnormal blood pressure (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) before vaccination; abnormal
  • Laboratory indicators out of the specified ranges (i.e., out of 1.5x of or LLN), or with clinical significance as judged by the physician.
  • Current/long-term history of alcohol abuse and/or history of drug abuse.
  • Any other factors judged by investigator that may affect the safety of the subject or evaluation of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    LY

    Young adult subjects received low dose of BV211

    Biological: Recombinant Zoster Vaccine

  • Experimental
    HY

    Young adult subjects received high dose of BV211

    Biological: Recombinant Zoster Vaccine

  • Placebo comparator
    Placebo

    Young adult subjects received placebo

    Biological: Placebo

  • Experimental
    LO

    Old adult subjects received low dose of BV211

    Biological: Recombinant Zoster Vaccine

  • Experimental
    HO

    Old adult subjects received high dose of BV211

    Biological: Recombinant Zoster Vaccine

  • Active comparator
    Control Vaccine

    Old adult subjects received control vaccine

    Biological: Zoster Vaccine Recombinant, Adjuvanted

Interventions

06

What researchers measure

Primary outcomes

  1. Safety in terms of adverse reactions/events

    Incidence rates of adverse reactions/events (ADRs/AEs)

    Time frame: 30 mins, 0-7 days, 8-30 days and 0-30 days

  2. Safety in terms of laboratory-based AEs

    Incidence rates of abnormal laboratory indicators

    Time frame: 3 days after each vaccination

  3. Safety in terms of SAEs

    Incidence rates of SAEs

    Time frame: Within 6 months after full vaccination

  4. Safety in terms of Adverse Events of Special Interest

    Incidence rates of AESI

    Time frame: Within 6 months after full vaccination

Secondary outcomes

  1. Immunogencity in terms of GMT by ELISA or FAMA

    GMC of anti-gE antibody and GMT of anti-VZV antibody

    Time frame: Days 1, 30, 60, 90 and 240

  2. Immunogencity in terms of Seroconversion Rates

    Seroconversion rates of anti-gE and anti-VZV antibody responses

    Time frame: Days 30, 60, 90 and 240

  3. Immunogencity in terms of Geometric Mean Fold Increase

    GMFI of anti-gE and anti-VZV antibody responses

    Time frame: Days 30, 60, 90 and 240

  4. Immunogencity in terms of Cellular immunity

    Frequency of CD4+ and CD8+T cells that express at least one cytokine

    Time frame: Days 1, 90 and 240

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Jan 2024, 5 months later.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2023
First posted
Feb 8, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Jan 31, 2024
CompletionEst.
Jul 31, 2024
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05718037
Lead sponsor
Wuhan BravoVax Co., Ltd.
Collaborators
Shanghai BravoBio Co., Ltd.
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Jan 31, 2024 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Feb 8, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion